Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) EBITDA Margin (2021 - 2025)

Historic EBITDA Margin for Allogene Therapeutics (ALLO) over the last 4 years, with Q1 2024 value amounting to 295327.27%.

  • Allogene Therapeutics' EBITDA Margin rose 245927300.0% to 295327.27% in Q1 2024 from the same period last year, while for Dec 2024 it was 1166927.27%, marking a year-over-year decrease of 8318809600.0%. This contributed to the annual value of 1166927.27% for FY2024, which is 8318809600.0% down from last year.
  • As of Q1 2024, Allogene Therapeutics' EBITDA Margin stood at 295327.27%, which was up 245927300.0% from 401533.33% recorded in Q4 2023.
  • In the past 5 years, Allogene Therapeutics' EBITDA Margin ranged from a high of 2.75% in Q4 2021 and a low of 401533.33% during Q4 2023
  • Moreover, its 4-year median value for EBITDA Margin was 276577.27% (2023), whereas its average is 230243.62%.
  • In the last 5 years, Allogene Therapeutics' EBITDA Margin crashed by 2000000000bps in 2022 and then skyrocketed by 409338400bps in 2023.
  • Allogene Therapeutics' EBITDA Margin (Quarter) stood at 2.75% in 2021, then tumbled by -13164303bps to 362473.08% in 2022, then dropped by -11bps to 401533.33% in 2023, then rose by 26bps to 295327.27% in 2024.
  • Its EBITDA Margin was 295327.27% in Q1 2024, compared to 401533.33% in Q4 2023 and 276577.27% in Q3 2023.